A major weapon used by the immune system to combat infection is the secretion of antibody molecules into bodily fl uids. Antibodies, which bind to and eliminate foreign antigens, represent soluble versions of the cell surface Ig proteins that act as the B cell receptor for antigen (BCR). More than 70 yr ago, antibodies were found to alter their antigen-binding properties over the course of an immune response (1) . The term "maturation of the immune response" was subsequently coined to describe the increase in antibody affi nity that is now recognized to be a defi ning characteristic of T cell-dependent (TD) humoral immune responses (2) .
To secrete antibody, antigen-activated B cells must fi rst diff erentiate into plasma cells. During TD immune responses, plasma cells are initially produced in transient extrafollicular proliferative foci (3) but are subsequently derived from B cells participating in the follicular germinal center (GC) reaction (4, 5) . Evidence that GCs might be connected with maturation of the serum antibody response was provided by the discovery that somatic hypermutation (SHM) of Ig genes occurs in GCs (6) and that rare mutant clones expressing BCRs with increased affi nity for the immunizing antigen preferentially survive there (4, 7) . Nevertheless, the precise factors that cause GC B cells to diff erentiate into plasma cells and, thus, drive affi nity maturation of the antibody response remain unclear (8) . In vitro experiments have suggested that stochastic or nonselective mechanisms are of primary importance in the regulation of plasma cell diff erentiation (9) . On the other hand, indirect evidence suggests that plasma cell diff erentiation of GC B cells may be more selective, with only those cells that exceed a threshold antigen affi nity contributing to the antibody response (10, 11) . Distinguishing between these two possibilities has proven diffi cult because current experimental models do not allow affi nity-based selection and plasma cell diff erentiation of GC B cells to be comprehensively tracked in vivo.
High affi nity germinal center B cells are actively selected into the plasma cell compartment
A hallmark of T cell-dependent immune responses is the progressive increase in the ability of serum antibodies to bind antigen and provide immune protection. Affi nity maturation of the antibody response is thought to be connected with the preferential survival of germinal centre (GC) B cells that have acquired increased affi nity for antigen via somatic hypermutation of their immunoglobulin genes. However, the mechanisms that drive affi nity maturation remain obscure because of the diffi culty in tracking the affi nity-based selection of GC B cells and their differentiation into plasma cells. We describe a powerful new model that allows these processes to be followed as they occur in vivo. In contrast to evidence from in vitro systems, responding GC B cells do not undergo plasma cell differentiation stochastically. Rather, only GC B cells that have acquired high affi nity for the immunizing antigen form plasma cells. Affi nity maturation is therefore driven by a tightly controlled mechanism that ensures only antibodies with the greatest possibility of neutralizing foreign antigen are produced. Because the body can sustain only limited numbers of plasma cells, this "quality control" over plasma cell differentiation is likely critical for establishing effective humoral immunity.
The SW HEL Ig knock-in mouse model was developed to analyze TD B cell responses to the protein antigen hen egg lysozyme (HEL) conjugated to the sheep RBC (SRBC) carrier (12) . SW HEL B cells express the anti-HEL BCR encoded by the high affi nity mAb HyHEL10 and can undergo both class switch recombination and SHM (13) . Adoptive transfer of small numbers of SW HEL B cells into CD45.1 congenic recipients and challenge with HEL-SRBC results in a typical TD immune response dominated by secretion of IgG1 antibodies derived from donor SW HEL B cells (12) . Responding SW HEL B cells can be tracked with precision by virtue of their expression of the anti-HEL BCR and the CD45.2 allotypic marker. The recombinant mutant HEL protein (HEL 3X ) binds HyHEL10 with >10,000-fold lower affi nity than wild-type HEL (HEL WT ) (14) . HEL 3X -SRBC triggers migration of responding SW HEL B cells into GCs but is ineff ective at eliciting an extrafollicular plasma cell response (14) . In this report we exploit the low affi nity of HEL 3X to develop a system in which the affi nity-based selection of GC B cells and their diff erentiation into plasma cells can be followed. This approach revealed that affi nity maturation of TD antibody responses is driven by a mechanism that permits only GC B cells that have acquired high affi nity for antigen to diff erentiate into plasma cells.
RESULTS AND D I S C U S S I O N
When SW HEL B cells are challenged with either high affi nity (HEL WT -SRBC) or low affi nity (HEL 3X -SRBC) antigen in CD45.1 congenic recipient mice, similar frequencies of donor-derived (CD45.2 + ) GC B cells are produced at over the fi rst 15 d of the response (14) , and these cells undergo equivalent rates of class switch recombination to IgG1 (Fig.  1 A) . The extent of SHM measured during the early stages of 
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the GC response (day 5) also does not diff er ( Fig. 1 B) . However, as the responses progress, GC B cells responding to the lower affi nity HEL 3X -SRBC accumulate somatic mutations faster and by day 15 contain signifi cantly more mutations per Ig heavy chain variable region gene than GC B cells responding to HEL WT -SRBC (Fig. 1 B) . These observations confi rm previous analyses of TD antihapten responses showing similar rates of SHM when initial antigen affi nity is high or low but enhanced selection for mutated variable regions in B cells with low initial antigen affi nity (15) .
SW HEL B cells challenged with HEL 3X -SRBC do not produce the burst of extrafollicular plasma cells that typically peaks around day 5 of responses to higher affi nity antigens such as HEL WT -SRBC (14) . As a result, the levels of both total anti-HEL antibody (14) and anti-HEL IgG1 (Fig. 1 C) present at day 5 are ‫-001ف‬fold lower when SW HEL B cells are challenged with HEL 3X -SRBC compared with HEL WT -SRBC. Nevertheless, the concentration of anti-HEL IgG1 in recipient serum increases progressively from days 5 to 20 of the response to HEL 3X -SRBC ( Fig. 1 C) . This antibody is derived from SW HEL donor B cells, because it is not detected in recipients receiving HEL 3X -SRBC alone (unpublished data). To examine whether the antibodies elicited in response to HEL 3X undergo affi nity maturation, serum anti-HEL IgG1 present at day 15 of the two responses was tested by ELISA for binding to HEL WT and HEL 3X . As expected, the IgG1 produced in response to HEL WT -SRBC bound effi ciently to HEL WT but showed negligible binding to HEL 3X (Fig. 1 D) . In contrast, the serum anti-HEL IgG1 from recipients challenged with HEL 3X -SRBC showed almost equivalent binding to HEL WT and HEL 3X (Fig. 1 D) , indicating that affi nity maturation to HEL 3X had indeed occurred.
To track the appearance and ultimate fate of GC B cells acquiring increased affi nity for HEL 3X , donor-derived B cells within the spleens of mice immunized with HEL 3X -SRBC were stained directly with fl uorescently labeled HEL 3X at days 5, 10, and 15 of the response (Fig. 2) . Analysis of CD45.2 + donor cells revealed a progressive increase in HEL 3X binding in mice challenged with HEL 3X -SRBC but not HEL WT -SRBC (Fig. 2) . When HEL 3X binding was counterstained for surface IgG1 so that HEL 3X binding by IgG1 + responders could be visualized independently of BCR density, a distinct population of IgG1 + B cells with uniformly increased affi nity for HEL 3X was evident by day 10 of the HEL 3X -SRBC response and subsequently dominated the IgG1 + donor population by day 15 (Fig. 2 ). This population was not apparent at any stage of the response to HEL WT -SRBC (Fig. 2) , indicating that the cells were specifi cally selected because of their increased affi nity for HEL 3X .
To determine whether B cells with high affi nity for HEL 3X carry specifi c somatic mutations that increase their affi nity for HEL 3X , single donor-derived GC B cells were sorted from immunized mice, and their Ig heavy chain variable region genes were sequenced. By day 15 of the response to HEL 3X -SRBC, 82% (23 out of 28) of the clones analyzed carried a specifi c point mutation in the tyrosine 53 codon encoding its substitution with aspartate (Y53D HyHEL10 ; Fig. 3 A) . No selection of any heavy chain mutation was evident in day 15 GC B cells produced in response to HEL WT -SRBC (Fig. 3 A) , which was consistent with the proposition that the affi nity of the HEL WT -HyHEL10 interaction is too high to permit further affi nity maturation (16) . None of the 24 clones analyzed from the day 15 HEL WT -SRBC GC response contained a mutation in the Y53 HyHEL10 codon, indicating that the Y53D HyHEL10 mutation is selected specifi cally in response to HEL 3X -SRBC and is therefore likely to increase the affi nity of HyHEL10 for HEL 3X . This was confi rmed by sorting high affi nity anti-HEL 3X IgG1 + donor B cells (see gate in Fig. 2) , as subsequent sequence analysis revealed that 96% (23 out of 24) of these clones carried the Y53D HyHEL10 mutation (unpublished data). Analysis of the binding of HEL 3X to recombinant wildtype and Y53D-mutated HyHEL10 IgG1 antibodies showed that the Y53D HyHEL10 mutation increases the affi nity of Hy-HEL10 for HEL 3X by ‫-58ف‬fold (Fig. 3 B) . This affi nity increase was also evident from the ability of the mutated form of HyHEL10 to recognize plate-bound HEL 3X effi ciently in ELISA under conditions in which binding of wild-type HyHEL10 to HEL 3X was virtually undetectable (Fig. 3 C) . Computer modeling revealed that the arginine side chain introduced at position 101 of HEL (D101R HEL ) to produce HEL 3X (14) is likely to cause a major steric confl ict with the phenol group of Y53 HyHEL10 and that this confl ict is resolved by the Y53D HyHEL10 substitution (Fig. S1 , available at http:// www.jem.org/cgi/content/full/jem.20061254/DC1).
To examine the selection of the Y53D HyHEL10 mutation over the course of the response to HEL 3X -SRBC, Ig heavy chain gene sequence analysis of single GC B cells and plasma cells was performed on days 5, 10, and 15. On day 5, the Y53D HyHEL10 mutation was not detectable in either the GC or the small plasma cell compartment (Fig. 4 A) , which was consistent with the absence of high affi nity anti-HEL 3X B cells at this time point (Fig. 2) . By day 10, however, this mutation was detectable in some GC B cells (22% of sequences) but was already present in the great majority of splenic plasma cells (86% of sequences). Similar domination of the GC B cell population by this mutation was not evident until day 15 (Fig.  4 A) . Because hypermutated plasma cells must have derived from GC B cell precursors, this result shows that GC B cells generated in response to HEL 3X -SRBC do not undergo stochastic diff erentiation into plasma cells but instead diff erentiate upon acquisition of the high-affi nity Y53D HyHEL10 mutation. Accordingly, Y53D-mutated clones that had left the GC and diff erentiated into plasma cells by day 10 of the response had a signifi cantly lower overall rate of SHM than the Y53D-mutated clones that remained within the GC compartment (2.2 vs. 4.6 mutations/clone, respectively; P = 0.02).
To monitor affi nity-based regulation of post-GC plasma cell diff erentiation more directly, we next challenged donor B cells from SW HEL × Blimp gfp/+ mice with HEL 3X -SRBC. Plasma cells generated in Blimp gfp/+ mice express GFP under the control of the Blimp-1 promoter and, thus, can be detected via intrinsic green fl uorescence (17) . By using SW HEL × Blimp gfp/+ donor B cells in conjunction with our method for identifying somatically mutated B cells with high affi nity for HEL 3X (Fig. 2) , we directly assessed the antigen affi nity of post-GC IgG1 + plasma cells in the spleen. Analysis of GFP expression by low and high affi nity donor-derived IgG1 + B cells on day 10 of the response to HEL 3X -SRBC clearly demonstrated that GFP-expressing plasma cells originated almost exclusively from GC precursors that had acquired a high affi nity anti-HEL 3X BCR (2.54% of high affi nity compared with 0.27% of low affi nity cells; Fig. 4 B) . These GFP + cells also had low but detectable levels of surface CD45.2 and IgG1 (Fig. 4 B and not depicted), as is typical of plasma cells (14) . Because >95% of high affi nity clones detected by HEL 3X binding have the Y53D HyHEL10 mutation, most of these GFP + plasma cells are likely to secrete antibodies carrying this amino acid change. Indeed, the serum IgG1 found in mice challenged with HEL 3X -SRBC shows almost identical antigen-binding characteristics to Y53D-mutated HyHEL10 (Fig. 1 D and Fig. 3 C) .
The model system described in this report provides a unique window into the GC reaction by allowing the appearance, selection, and diff erentiation of high affi nity somatically mutated B cells to be followed throughout the response. We have used this system to demonstrate that high affi nity B cell specifi cities generated within the GC are harnessed to drive affi nity maturation of the antibody response 
by a mechanism that ensures their rapid and selective diff erentiation into plasma cells.
Because low affi nity B cells survive within GCs without undergoing plasma cell diff erentiation (Fig. 4 B) , it is apparent that the affi nity-dependent mechanism that regulates plasma cell diff erentiation from GC B cell precursors operates independently of the processes that govern GC B cell survival. The existence of this mechanism was not predicted from in vitro experiments, because these show that B cells can undergo stochastic plasma cell diff erentiation without requiring a BCR signal (9) . This would suggest that specifi c controls exist within the GC microenvironment that suppress plasma cell diff erentiation in the absence of signals from high affi nity antigen.
The requirement for antigen-dependent signals to drive plasma cell diff erentiation from GC B cells presents an interesting parallel with the regulation of the extrafollicular plasma cell response. These early plasma cells arise independently of the GC reaction (3) but are similarly biased toward high affi nity specifi cities or epitopes present at high density (14) . Therefore, the BCR-antigen interaction appears to play a key role in regulating TD plasma cell diff erentiation both before and after GC formation. It is possible that BCR signaling could facilitate plasma cell diff erentiation via the induction of Bcl-6 degradation (18) and subsequent lifting of Blimp-1 repression (19) . Alternatively, responding B cells may stochastically commence plasma cell diff erentiation but require BCR signals to survive beyond the very earliest stages of this process. Whatever the precise mechanism, it is apparent that the immune system places a high priority on ensuring that it devotes resources primarily to the production of relatively high affi nity antibodies that are most likely to be biologically eff ective. The importance of this stringent regulation of plasma cell differentiation is perhaps underscored by the relatively permissive affi nity requirements for GC B cells to enter the memory B cell compartment (10, 20) . The emphasis on quality control of in vivo plasma cell diff erentiation may have been a critical development during the evolution of the immune system. Because the body is known to have only a relatively limited capacity within the specialized microenvironments that sustain plasma cells (21, 22) , it can be seen that tight control over the specifi cities that enter the plasma cell compartment would be essential for ensuring that the antibodies that are produced provide eff ective immune protection.
MATERIALS AND METHODS
Mice and procedures. SW HEL mice (13) , Blimp gfp/+ mice (17), mutant HEL proteins (14) , conjugation of HEL to SRBC, and the adoptive transfer system (12) have been previously described. SW HEL spleen cells were not purifi ed before transfer. Mice were housed in a specifi c pathogen-free environment at Centenary Institute, and experiments were approved by the University of Sydney Animal Ethics Committee.
ELISA. Serum anti-HEL antibody levels were analyzed by ELISA as previously described (13) . The specifi city of serum IgG1 antibodies for HEL WT and HEL 3X was determined by coating the ELISA plates with the respective antigens. The relative affi nities of HyHEL10 WT and HyHEL10 Y53D for HEL 3X were determined by capture ELISA. 5 μg/ml each of soluble Hy-HEL10 WT and HyHEL10 Y53D IgG1 antibodies was captured by plate-bound anti-mouse IgG1. Subsequent binding of HEL 3X was detected with biotinylated HyHEL9, which recognizes an epitope on HEL distinct from that bound by HyHEL10. Nonlinear regression based on a sigmoidal binding curve was performed using software (Prism; GraphPad) to fi nd the curve-fi t and calculate the half-maximal binding concentration and relative affi nity of HyHEL10 WT and HyHEL10 Y53D for HEL 3X .
Flow cytometry and single cell sorting. Splenocytes were prepared, stained for surface molecules with monoclonal antibodies, and analyzed on a FACSCalibur (BD Biosciences) as previously described (14) . To track affi nity maturation, cells were stained with recombinant HEL 3X conjugated to Alexa Fluor 647 (Invitrogen). For analysis of Blimp-GFP expression, CD45.2 was conjugated to Pacifi c blue (Invitrogen) to allow identifi cation of donor-derived cells and data acquired on a fl ow cytometer (LSR II; BD Biosciences). Single cells were sorted on a FACSAria (BD Biosciences) as previously described (14) . The gates used for single cell sorting of GC B cells (CD45.2 hi , syndecan-1 − ) and plasma cells (CD45.2 int , syndecan-1 + ) were the same as those previously described (14) . These gates have been verifi ed through localization of antibody secreting activity (12) and high levels of intracellular Ig staining (14) to cells in the plasma cell gate and demonstration of high levels of GL7, PNA, and Fas on cells in the GC gate (12, 14) . SHM analysis. The HyHEL10 Ig heavy chain variable region gene was amplifi ed from single-responding SW HEL donor B cells and sequenced as previously described (14) . Translated sequences were aligned with the original HyHEL10 protein sequence to determine the position and signifi cance of the mutations, as previously described (12) . An unpaired t test was used to calculate the probability (p-value) when comparing SHM frequency per clone in diff erent responding populations.
Expression of wild-type and Y53D-mutated HyHEL10 IgG1 antibodies. The canonical T to G mutation encoding the Y53D HyHEL10 substitution was introduced by PCR mutagenesis into a pcDNA3 vector (Invitrogen) encoding the HyHEL10 γ1-secreted Ig heavy chain. Wild-type and mutant heavy chain constructs were transiently expressed in Chinese hamster ovary cells along with wild-type HyHEL10 κ light chain construct, and culture supernatants were collected and concentrated.
Online supplemental material. Fig. S1 shows Rasmol wire frame representations based on the HEL-HyHEL10 complex that model the eff ects of the D101R HEL and Y53D HyHEL10 substitutions on the interaction. Online supplemental material is available at http://www.jem.org/cgi/content/ full/jem.20061254/DC1.
